PRISM BioLab Co Ltd

TSE • Healthcare • Biotechnology • Quote as of 10/30/2026

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeTSE

Market Capitalization4,879.25 mln

Float17.25 mln

Earnings Date05/14/2025

Piotroski F-Score

3 / 9

Below average

Beneish M-Score

-0.34

Highly suspicious

Relative Strength

27 / 100

Underperforming

Pre-Tax Margin

-118%

Severely loss-making

ROE

-36.78

Deeply negative

Altman Z-Score

4.56

Strong

Business Description

PRISM BioLab is a Japanese pharmaceutical research company founded in 2006 and headquartered in Fujisawa. The company uses its own drug discovery technology, called PepMetics, to develop new treatments for cancer and liver disease, with two compounds currently in Phase II clinical trials. It also works alongside Receptor.AI to build an artificial intelligence-enhanced drug discovery platform.

Key Fundamentals

EPS-23.66

ROE-36.78

RPS19.98

ROIC-172

ROA-29.92

EBITDA, mln-873

EV / EBITDA-4.41

EV / EBIT-4.41

Revenue, mln737

EV / Revenue5.22

Quote Details

Last 132.00

Change 2 (1.54%)

Open 130.00

Volume 63,700

Turnover 8,408,400

Average Volume 79,857

Financial Ratios

Pre-Tax Profit Margin-118

Leverage Ratio1.31

Current Ratio4.21

Price / Book3.26

Price / Tangible Book3.26

Price / Sales8.34

Financial Strength

Altman Z-Score4.56

Piotroski F-Score 3 / 9

Beneish M-Score-0.34

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	0%	64 / 100
1 Month	-20.96%	4 / 100
2 Months	-10.81%	17 / 100
6 Months	-28.65%	7 / 100
1 Year	-20.48%	14 / 100